HHS publishes a draft policy on 503A compounding with certain peptides

On October 30, 2026, HHS said it does not intend to take enforcement action against certain 503A compounders using peptides in its Appendix A, and this covers what that means.

Basics5 min read

Key takeaway

HHS published a draft, non-binding policy on October 30, 2026 under docket HHS-OASH-2026-0496. It says HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound with a peptide listed in the policy’s Appendix A. It applies while FDA builds the 503A bulks list by rulemaking. The Federal Register text does not name the peptides.

At a glance

Article typeBasics
TopicLaw & regulation
Studies cited0
Related productsResearch peptide catalog

The HHS 503A peptide policy reached the Federal Register on October 30, 2026. In document 2026-22192 (91 FR 68526), the Secretary of Health and Human Services announced a draft “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.”

Quick answer: Does the HHS notice approve any peptide? No. Compounded drugs stay unapproved, no peptide joins the 503A bulks list, and HHS says the policy is not binding. The notice does not mention companies that sell peptides as research chemicals.

This article summarizes public regulatory records. It is not legal advice.

What does the Federal Register notice say?

The notice comes from the Office of the Secretary of HHS and is labeled a “Notice of availability” (HHS, 2026). It is signed by Secretary Robert F. Kennedy, Jr. Its core sentence says HHS “does not intend to take enforcement action” against “a State-licensed pharmacy, Federal facility, or licensed physician” compounding a drug product with “a peptide bulk drug substance found in Appendix A.”

As reasons, it cites “the Pharmacy Compounding Advisory Committee meetings and data regarding utilization of peptides” and “the lack of availability of approved products.” Its stated aim is “to expand and improve patient access.”

It also sets limits. The notice says compounded drugs “are not FDA-approved,” so FDA does not review their safety, effectiveness or quality before they are sold. HHS may revisit the policy, in whole or in part, if “a safety signal or product quality issue arises.” And the policy “does not establish any rights for any person and is not binding on HHS or the public.”

Which peptides are in Appendix A?

The Federal Register text does not list them. It points to the policy document on the HHS website and to Regulations.gov, and tells them to use the HHS site “to find the most current version of the policy.” Regulations.gov files that document as HHS-OASH-2026-0496-0001 (Regulations.gov, 2026). We could not retrieve either copy on November 17, 2026, so we report only what the Federal Register text says.

On July 23 and 24, 2026, FDA’s Pharmacy Compounding Advisory Committee discussed seven peptides nominated for the 503A bulks list (Table 1). The notice does not say which of them, if any, appear in Appendix A. FDA’s meeting page listed briefing documents but no minutes or vote results when we checked (FDA, 2026a).

Table 1

Peptides on the July 2026 advisory committee agenda

Meeting day Bulk drug substances (free base and acetate)
July 23, 2026 BPC-157; KPV; TB-500; MOTS-c
July 24, 2026 Emideltide (DSIP); Semax; Epitalon

What does it change, and what does it not change?

It changes HHS’s stated enforcement stance for the three kinds of 503A compounders named above when they use an Appendix A peptide. The Federal Register text states no other conditions. We could not check whether the policy document itself sets more.

It does not change the following:

  • Approval. No peptide becomes an approved drug, and compounded drugs remain unapproved.
  • The 503A bulks list. FDA says a 503A compounder may use a bulk substance only if it meets a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA’s bulks list (FDA, 2026b). The notice adds no peptide to that list. It says FDA’s future rulemakings “may propose adding some or all of these peptides.”
  • 503B outsourcing facilities. The notice addresses section 503A only.
  • Research chemical sales. The notice does not mention them.

Who does it affect?

Compounders: state-licensed pharmacies, federal facilities and licensed physicians are the only entities the notice names. Prescribers, patients and states: not named; state pharmacy law is not addressed. Sellers and researchers: FDA says it has warned companies selling GLP-1 products “falsely labeled” for research purposes (FDA, 2026e), and our guide to FDA warning letters covers the pattern. Research-grade peptides, like those in our catalog, are sold for laboratory research use only, not for human or veterinary use, and are not compounded drugs.

What happens next?

The notice allowed written comments “until 2 weeks after date of publication.” Regulations.gov records the comment period as ending at 11:59 p.m. Eastern on November 13, 2026, and showed 115 posted comments on November 17 (Regulations.gov, 2026). The Federal Register showed no final version of the policy and no FDA proposal adding peptides to the 503A bulks list through November 17.

Table 2

Key dates for the HHS peptide policy

Date Event
April 16, 2026 Federal Register notice of the advisory committee meeting (2026-07361)
July 23–24, 2026 Pharmacy Compounding Advisory Committee discusses seven peptides
October 30, 2026 Notice published (2026-22192, 91 FR 68526)
November 13, 2026 Comment period closes on Regulations.gov
November 17, 2026 115 comments posted; no final version found

How does it fit the earlier history?

FDA has placed many nominated 503A substances in interim categories while it builds the bulks list; our explainers on the 503A categories and 503A versus 503B compounding cover that framework. By April 22, 2026, FDA’s safety-risks page listed BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon and emideltide among substances “previously in category 2” that their nominators had withdrawn (FDA, 2026c). FDA gave notice of the July advisory committee meeting on April 16 (FDA, 2026d). Our overview of peptides and the FDA in 2026 puts these steps in order.

Frequently asked questions about the HHS peptide policy

Does the policy make compounded peptides FDA-approved?

No. The notice states that compounded drugs are not FDA-approved. It describes enforcement discretion, not approval.

Which peptides does it cover?

Those in Appendix A of the policy document on the HHS website. The Federal Register text does not name them.

Does it cover research-use-only peptide sellers?

The notice names only state-licensed pharmacies, federal facilities and licensed physicians compounding drug products. It does not mention research chemical sellers.

What to know now

  • Scope: 503A compounding by state-licensed pharmacies, federal facilities and licensed physicians, using Appendix A peptides.
  • Status: draft, not binding, revisable on a safety signal or quality issue.
  • Not changed: no approvals, no additions to the 503A bulks list, nothing on 503B.
  • Comments: closed November 13, 2026; 115 posted by November 17.

What we’re watching

A final or revised version of the policy on the HHS website or in the Federal Register. Any FDA rulemaking that proposes peptides for the 503A bulks list. Minutes or vote results from the July 2026 advisory committee meeting.

Also in the library

Sources: Office of the Secretary 2026, Federal Register, 91; Regulations.gov 2026; U.S. Food and Drug Administration 2026a, July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee; U.S. Food and Drug Administration 2026b, Bulk drug substances used in compounding under section 503A of the FD&C Act; U.S. Food and Drug Administration 2026c; U.S. Food and Drug Administration 2026d, Federal Register; U.S. Food and Drug Administration 2026e, FDA’s concerns with unapproved GLP-1 drugs used for weight loss. All 7 citations

Back to the research library

References

  1. Office of the Secretary, U.S. Department of Health and Human Services. (2026, October 30). Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances; notice of availability (Docket No. HHS-OASH-2026-0496; FR Doc. 2026-22192). Federal Register, 91, 68526. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
  2. Regulations.gov. (2026). Docket HHS-OASH-2026-0496: HHS enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Retrieved November 17, 2026, from https://www.regulations.gov/docket/HHS-OASH-2026-0496
  3. U.S. Food and Drug Administration. (2026a). July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (content current as of August 6, 2026). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
  4. U.S. Food and Drug Administration. (2026b). Bulk drug substances used in compounding under section 503A of the FD&C Act (content current as of May 14, 2026). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  5. U.S. Food and Drug Administration. (2026c). Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  6. U.S. Food and Drug Administration. (2026d, April 16). Pharmacy Compounding Advisory Committee; notice of meeting; establishment of a public docket; request for comments (Docket No. FDA-2025-N-6895; FR Doc. 2026-07361). Federal Register. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
  7. U.S. Food and Drug Administration. (2026e). FDA’s concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026). https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss